2019

August 11, 2019
Patients Who Receive Positively Framed Biosimilar Information More Than Twice as Likely to Accept a Switch

July 19, 2019
Amgen and Allergan Launch Mvasi and Kanjinti, the First Anticancer Biosimilars, in the United States

May 13, 2019
Updated: Interchangeable Biosimilars: FDA Finalizes Guidance

March 12, 2019
Sagent Acquires US Facility for Biosimilar Production

March 12, 2019
National Cancer Institute Director Ned Sharpless named acting FDA commissioner

January 3, 2019
January MedPAC Recommendations: Rebates & Biosimilars

2018

July 18, 2018
FDA Commissioner Scott Gottlieb on the release of the FDA’s Biosimilars Action Plan

May 22, 2018
FDA launches video series about biosimilar and interchangeable products

April 3, 2018
CMS Final Rule Lowers Maximum Co-Payment Amount for Biosimilars

2017

November 16, 2017 
Update: How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline

November 6, 2017 
CMS Shift on Biosimilar Reimbursement Under Part B: What to Expect

October 23, 2017 
FDA Taking New Steps to Better Inform Physicians about Biosimilars Through Education about these Potentially Cost-Saving Options

September 28, 2017
Marketing Approval for Infliximab Biosimilar 100mg “Nichi-Iko” in Japan